Verma Rajesh, Vasudevan Biju, Pragasam Vijendran, Neema Shekhar
Department of Dermatology, Command Hospital, Pune, Maharashtra, India.
Indian J Pharmacol. 2013 Nov-Dec;45(6):634-5. doi: 10.4103/0253-7613.121386.
Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 52-year-old male who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
伊马替尼是一种特异性酪氨酸激酶抑制剂，是一种新型抗癌药物，在治疗慢性粒细胞白血病方面已显示出卓越疗效。它通常耐受性良好，副作用较少。最常报告的不良事件是斑丘疹和眶周水肿。5%的患者会出现严重不良反应。这种药物极少报告有剥脱性皮炎。我们报告一例52岁男性患者，最初表现为斑丘疹，在继续用药后发展为红皮病。
